Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelabresib and Ruxolitinib in JAKi Treatment Naive Myelofibrosis Patients
NCT04603495Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of pelabresib in myelofibrosis (MF), sponsored by Novartis. Started Apr 2021; status: active, not recruiting.
02
Drugs
pelabresib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04603495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603495.